药代动力学
氟伏沙明
托莫西汀
阿托莫西汀
代谢物
药理学
再摄取抑制剂
化学
内科学
抗抑郁药
医学
注意缺陷多动障碍
氟西汀
血清素
哌醋甲酯
精神科
受体
海马体
作者
Ioana Todor,Adina Popa,Maria Adriana Neag,Dana Muntean,Ioana Corina Bocşan,Anca Dana Buzoianu,Laurian Vlase,Ana-Maria Gheldiu,Corina Briciu
出处
期刊:Pharmacology
[S. Karger AG]
日期:2016-11-04
卷期号:99 (1-2): 84-88
被引量:9
摘要
Attention deficit hyperactivity disorder (ADHD) is frequently associated with other psychiatric pathologies. Therefore, the present study investigated a possible pharmacokinetic interaction between atomoxetine (ATX), a treatment option for ADHD, and an antidepressant, namely, fluvoxamine (FVX).Designed as an open-label, non-randomized clinical trial, the study included 2 periods. In period 1 (reference), each subject received ATX 25 mg (single-dose), whereas in period 2 (test), all subjects were given a combination of ATX 25 mg + FVX 100 mg, following a 6-day pretreatment regimen with the enzymatic inhibitor. Non-compartmental methods were employed to determine the pharmacokinetic parameters of ATX and its main active metabolite (glucuronidated form), 4-hydroxyatomoxetine-O-glucuronide.The results revealed significant differences between the study periods for Cmax, AUC0-t and AUC0-∞ values corresponding to ATX and its metabolite. Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor.FVX had a modest effect on the pharmacokinetics of ATX and 4-hydroxyatomoxetine-O-glucuronide. The presence or absence of any clinical consequences associated with this pharmacokinetic drug-drug interaction needs to be established in future studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI